22 Jul
#NewTrialAnnouncement
PharmaSols is delighted to be working with UNITY Biotechnology, Inc. (UNITY) on their latest ophthalmologic study UBX1325-02, across multiple sites in Australia and New Zealand.
The study is a Phase 2a, Prospective, Multicentre, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Oedema (DME).
UNITY’s goal with UBX1325 is to transformationally improve real-world outcomes for patients with DME, nAMD, and DR.
UNITY and PharmaSols look forward to forging a strong on-going relationship. As UNITY expands its global footprint with clinical studies, they are very excited to include AU and NZ in this important effort.
Find out more https://lnkd.in/g_MXh9U
Other News
May 2024 (1)
March 2024 (1)
February 2024 (1)
December 2023 (1)
November 2023 (1)
October 2023 (1)
September 2023 (2)
August 2023 (1)
July 2023 (1)
June 2023 (2)
May 2023 (3)
April 2023 (1)
March 2023 (2)
The Go-to region for clinical trials (1)
HiRO – our global advantage, tailored solutions and key partnerships (1) (1)
HiRO – an emerging full-service global CRO (1)
HiRO – Top CRO in APAC 2022 (1) (1)
November 2022 (1)
October 2022 (1)
September 2022 (1)
August 2022 (1)
July 2022 (1)
June 2022 (1)
May 2022 (1)
April 2022 (1)
March 2022 (1)
January 2022 (1)
December 2021 (1)
November 2021 (1)
October 2021 (2)
September 2021 (2)
August 2021 (3)
July 2021 (3)
June 2021 (2)
May 2021 (1)
April 2021 (2)
March 2021 (1)
February 2021 (1)
December 2020 (5)
November 2020 (1)
October 2020 (5)
September 2020 (1)
August 2020 (2)
May 2020 (5)
January 2024 (0)
